August 23, 2024

Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Metastatic castration-resistant prostate cancer (mCRPC) resistant to androgen receptor signaling inhibitors (ARSI) is often lethal. Liquid biopsy biomarkers for this deadly form of disease remain under investigation, and underpinning mechanisms remain ill-understood.

Me gusta

Guardar

Cite This Study

Chauhan et al. (Fri,) studied this question.

synapsesocial.com/papers/68e5b277b6db64358754b0f2 https://doi.org/https://doi.org/10.1158/1078-0432.ccr-24-1658

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The mutational landscape of lethal castration-resistant prostate cancer2012 · 2,589 citations
2metilene: fast and sensitive calling of differentially methylated regions from bisulfite sequencing data2015 · 561 citations
3Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability2016 · 331 citations
4<scp>PRMT</scp>1 regulates astrocytic differentiation of embryonic neural stem/precursor cells2017 · 35 citations
5cfNOMe — A single assay for comprehensive epigenetic analyses of cell-free DNA2020 · 70 citations

Me gusta

Guardar